RxDoctor Payments Data

May Lee, MD

Pulmonary Disease · Hobart, INNPI 1073556155

Payments from drug & device makers

$854in general payments, 2019–2025

Across 43 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$187
  • Boehringer Ingelheim$90
  • Sanofi$81
  • Mallinckrodt Hospital Products Inc.$72
  • Amgen$48
  • Lilly USA, LLC$45
  • plus $331 from 12 others

What the payments were for

  • Food & beverage$80995%
  • Education$455%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$854 in reported general payments places this provider in the 35th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$663,260
Medicare patients
632
Services billed
15,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter363$319,798
Breo ElliptaFluticasone/Vilanterol176$113,617
NucalaMepolizumab25$99,880
EliquisApixaban69$65,970
Breztri AerosphereBudesonide/Glycopyr/Formoterol72$63,279
Spiriva RespimatTiotropium Bromide53$43,571
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr54$42,710
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$26,413
Spiriva HandihalerTiotropium Bromide30$24,139
XareltoRivaroxaban28$16,956
SymbicortBudesonide/Formoterol Fumarate50$15,852
Albuterol Sulfate HfaAlbuterol Sulfate551$13,530
Fluticasone-SalmeterolFluticasone Propion/Salmeterol87$13,202
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate56$9,017
Arnuity ElliptaFluticasone Furoate18$6,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta$187$582,572636 claims
AstraZenecaBreztri Aerosphere, Symbicort$35$79,131122 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$90$69,98486 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Hobart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →